Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 1
2020 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC; INSIGHT Investigators. Wu YL, et al. Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29. Lancet Respir Med. 2020. PMID: 32479794 Clinical Trial.
Renal primary angiosarcoma.
Carnero López B, Fernández Pérez I, Carrasco Alvarez JA, Lázaro Quintela ME, López Jato C, Jorge Fernández M, Gentil González M, Vázquez Tuñas L, Castellanos Díez J. Carnero López B, et al. Among authors: lazaro quintela me. Clin Transl Oncol. 2007 Dec;9(12):806-10. doi: 10.1007/s12094-007-0144-y. Clin Transl Oncol. 2007. PMID: 18158986
[Analysis of differences between indication and prescription of gastroprotection in patients with risk factors treated with nonsteroidal anti-inflammatory agents: the GAP study].
Lanas A, Muñoz M, Caballero Correa M, Martínez Jiménez P; investigadores del estudio GAP. Lanas A, et al. Gastroenterol Hepatol. 2010 Feb;33(2):80-91. doi: 10.1016/j.gastrohep.2009.09.009. Epub 2009 Nov 22. Gastroenterol Hepatol. 2010. PMID: 19931944 Clinical Trial. Spanish.